



NEWS RELEASE

Hyphens Pharma Philippines launches new generation drug eluting stent

Manila, Philippines – Jul 5, 2010 – Hyphens Pharma Philippines, Inc., today launched Biomatrix® DES, a new generation drug eluting stent in collaboration and support of Philippine Society of Cardiovascular Catheterization and Interventions, Inc. (PSCCI). The launch, which coincided with the Society's Consultant's Forum, was attended by almost 60 interventional cardiologists in Metro Manila.

During the launch, Mr. John E. Shulze, Chief Technology Officer of Biosensors led an open discussion about the company's new generation drug eluting stent. Mr. Shulze is the key architect of Biomatrix™ drug-eluting stent systems. In the discussion, he shared the results of the LEADERS trial, a 2-year all-comers prospective randomized trial, confirming the benefits of Biomatrix™ DES while demonstrating the excellent procedural performance and clinical outcome.

In the Philippines, heart disease has become the number one cause of mortality among Filipinos. Advanced heart stents thus provide another strong tool to the physician's armamentarium against the rising trend of this disease.

"Biomatrix® DES is the choice coronary stent implantation treatment. We are delighted to introduce a proven drug eluting stent that have resulted in excellent patient outcome as demonstrated in numerous clinical trials," said Mr. Randy Yulo, President of Hyphens Pharma Philippines.

About Biomatrix™

Biomatrix® DES combines the proven safety of a drug eluting stent (DES) with an abluminal biodegradable polymer, the proven anti-restenotic efficacy of Biolimus A9™ drug and the proven flexibility of advanced stent design for enhanced deliverability.

About Hyphens Pharma Philippines, Inc.

We are a specialty pharmaceutical company focused on the sales and market development of innovative health care products in various therapeutic fields including Allergy & Ear-Nose-Throat and Interventional Cardiology. Together with our regional headquarters in Singapore, we work closely with key opinion leaders in the region to address unmet medical needs. For more information, please visit www.hyphens.com.sg.

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug eluting stents, bare metal stenting and open heart surgery. Its drug eluting stent programs include the BioMatrix™ stent and the BioFreedom™ stent, a completely polymer-free drug eluting stent. For more information, please visit www.biosensors.com.

Media Contact

Mr Ng Yiu Cheong
(65) 6338 8551
connect@hyphens.com.sg